Daratumumab-mediated elimination of these CD38⁺ immune regulatory cells may reduce local immune suppression within the myeloma microenvironment and allow positive immune effector cells to expand and contribute to antitumor response.

Is DARZALEX an immunosuppressant?

Darzalex isn't chemotherapy. It's a type of targeted therapy and is sometimes called immunotherapy. This means that Darzalex is designed to work with your immune system (your body's defense against infection).

How long can you take Daratumumab?

Official Answer. Darzalex is administered until signs of progression of multiple myeloma (MM) occur, or side effects become intolerable. Treatment durations of up to 25 months have been reported in clinical trials (range 0.1 month to 40.44 months).

What are the side effects of Daratumumab?

The most common side effects of DARZALEX^® include tiredness, nausea, diarrhea, constipation, vomiting, muscle spasms, joint pain, back pain, fever, chills, dizziness, trouble sleeping, cough, shortness of breath, swollen hands, ankles or feet, nerve damage causing tingling, numbness or pain, and cold-like symptoms ( ...

How long do Daratumumab side effects last?

These effects may last up to 6 months after your last dose. Tell all of your healthcare providers that you are receiving this medicine before you receive a blood transfusion.

Mechanism of action of daratumumab

Does daratumumab cause neuropathy?

In this pooled safety population, the most common adverse reactions (≥20%) were upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia.

Is daratumumab considered chemotherapy?

DARZALEX^® (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. DARZALEX^® is not chemotherapy. It is a targeted monoclonal antibody that helps slow or stop the progression of multiple myeloma in several ways.

Does daratumumab cause weight gain?

Weight gain of 5 pounds in one week (fluid retention) Swelling of your legs, ankles and/or feet.

How effective is daratumumab?

Daratumumab, Lenalidomide, and Dexamethasone

The overall response rate was 81%, with 34% of patients achieving a complete response or better and 63% achieving a very good partial response (VGPR) or better. The median response duration was not reached, and 91% of patients were free of disease progression at 12 months.

Is daratumumab approved for amyloidosis?

Subcutaneous Daratumumab Approved in Europe for Newly Diagnosed Light-Chain Amyloidosis, Pretreated Myeloma. The European Commission has granted marketing authorization for the expanded use of subcutaneous daratumumab for use in 2 new indications.

What is the longest survival rate for myeloma?

The overall 5-year survival rate for people with multiple myeloma is 54%. For the 5% of people who are diagnosed at an early stage, the 5-year survival rate is 75%. If the cancer has spread to a distant part of the body, the 5-year survival rate is 53%. Approximately 95% of cases are diagnosed at this stage.

Will myeloma come back?

If you have multiple myeloma, there's a good chance it will come back after successful treatment. When this happens, it's called recurrent or relapsed. If it doesn't respond to treatment or comes back within 60 days after your last therapy, it's known as refractory.

Does Daratumumab cause neutropenia?

Grade 3-4 neutropenia is a common adverse event in patients on daratumumab, Lonial noted. This happens most often when the drug is combined with another agent, such as pomalidomide, rather than when given as a single agent.

Can you drink alcohol with Daratumumab?

The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of daratumumab. pregnancy. It is best to use birth control while being treated with daratumumab and for at least three months after treatment has ended.

Is Daratumumab a monoclonal antibody?

Daratumumab (Darzalex[TM]) is a human monoclonal antibody (MAb) that targets CD38; a surface protein highly expressed across multiple myeloma (MM) cells.

How long is Darzalex infusion?

Be prepared: The first infusion of DARZALEX^® may take about 7 hours. Future infusions will take less time but may still take 3 to 4 hours. Forty percent of patients experienced an infusion reaction during the first infusion.

What is the half life of Daratumumab?

The mean (SD) estimated terminal half-life associated with linear clearance is approximately 18 (9) days. Population PK analyses indicated that the central volume of distribution and clearance of daratumumab increase with increasing body weight, supporting the body weight-based dosing regimen.

Who invented Daratumumab?

Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Daratumumab was given breakthrough therapy drug status in 2013, for multiple myeloma.

Is kyprolis a chemotherapy drug?

by Drugs.com

Kyprolis (carfilzomib) is a type of chemotherapy drug and a second-generation proteasome inhibitor. Kyprolis is used to treat multiple myeloma, which is a type of hematological malignancy, or blood cancer, that affects plasma cells.

What class of drug is Daratumumab?

Daratumumab is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells.

Is Daratumumab cytotoxic?

Preclinical studies showed that daratumumab may kill myeloma cells by complement-mediated cytotoxicity, by antibody-dependent cellular cytotoxicity, and by antibody-dependent cellular phagocytosis (1–3).

Can daratumumab cause high blood pressure?

A serious infusion reaction is an uncommon side effect of daratumumab. When this side effect occurs, it usually occurs with the first infusion. It may cause severe shortness of breath, high or low blood pressure, cough, wheezing, hives, itching, rash, nausea, vomiting, or chills.

When is daratumumab given?

Daratumumab attaches to the CD38 protein found on the surface of myeloma cells, enabling the immune system to target and kill it (Figure 1). How is daratumumab given? daratumumab is given every 2 weeks, and then every 4 weeks.

What is daratumumab made of?

Daratumumab is an immunoglobulin G1 kappa (IgG1k) human mAb that binds to a unique CD38 epitope on CD38-expressing cells with high affinity and was developed by the immunization of human immunoglobulin transgenic mice with recombinant CD38 protein [16]. de Weers et al.